Phreesia, Inc (PHR) Fair Value & Analysis
Healthcare · US · Market cap $580M
Phreesia, Inc
PHR · US
Fair value as of: Jun 24, 2026
From 23 valuation models · updated 8 days ago
Share price +5.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $6.74 – $27.22 · fair‑value band $3.76 – $6.57 · the $9.15 price screens above the $5.16 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Phreesia, Inc (PHR) currently trades at $9.15, while our model-based Fair Value estimate is $5.16 — implying the stock looks roughly 43.6% overvalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Phreesia, Inc generated revenue of $496M at a net margin of 1.9%. Revenue grew 12.9% year over year. It earns a return on equity of 2.9%. Net debt stands at $28.6M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Phreesia, Inc reported revenue of $481M in FY2026 versus $213M in FY2022, a compound +22.5%/yr. Reported net income was $2.3M in FY2026.
Is PHR fairly valued? → Check now
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $163.76 | $103.58 | -37% |
| Pro Medicus Limited PME | A$172.80 | A$32.25 | -81% |
| BrightSpring Health Services, Inc BTSG | $57.40 | $23.87 | -58% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $89.72 | $54.47 | -39% |
| M3, Inc MTHRY | $5.03 | $7.44 | +48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Phreesia, Inc (PHR) undervalued?
What is the fair value of PHR?
What is the quality score of PHR?
What is the revenue of Phreesia, Inc (PHR)?
What is the net profit margin of PHR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.